1. Market Research
  2. > Pharmaceutical Market Trends
Global Antirheumatics Pharmaceutical Market Forecast 2023

Global Antirheumatics Pharmaceutical Market Forecast 2023

  • June 2019
  • 316 pages
  • ID: 5786242
  • Format: PDF
  • NAVADHI Market Research


Table of Contents

Global antirheumatics market is expected to grow in near future as aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases help increase the demand for various arthritis treatments.

Global antirheumatics market is expected to be worth USD 56.88 billion by 2023.
As per NAVADHI Market Research, global antirheumatics pharmaceutical market will we worth USD 56.88 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

Antirheumatics had the second largest revenue share in Global pharmaceuticals market in FY 2018, and it is expected to retain it’s position even in 2023.

As per industry sources, about 1.3 million people suffer from rheumatoid arthritis (RA) in United States, 2.9 million in European Union and 1.4 million in Japan and most of the patients are women. With the increasing lifespans due to improved healthcare facilities more and more people are prone to rheumatoid arthritis.

This growth in antirheumatics market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global antirheumatics industry. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and specialty diseases market. Innovations in advanced biologics, nucleic acid therapeutics and cell therapies has attracted investments in the industry which is fueling this growth.

On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global antirheumatics industry. Antirheumatics companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the global antirheumatics market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug. Competition from generic manufacturers is also a concern for major brands. For example – Cipla in 2013 launched the biosimilar of etanercept under brand name Etacept for the treatment of rheumatic disorders which was cheaper alternative of Amgen and Pfizer’s hugely successful Enbrel brand.

On 3rd January 2019, Bristol-Myers Squibb Company which was ranked 7th based on their FY 2018 antirheumatics revenue announced their plan to acquire Celgene Corporation which was ranked 10th in the world for antirheumatics revenue. The acquisition is expected to cost around USD 90 billion to Bristol-Myers Squibb Company. Post-acquisition Bristol-Myers Squibb Company is expected to give tough competition to Pfizer for 3rd spot in global antirheumatics revenue.

Spanning over 267 pages and 180 exhibits, “Global Antirheumatics Pharmaceutical Market Forecast 2023” report provides in-depth analysis for the global antirheumatics pharmaceuticals market for the year FY2018 to FY2023, including market structure, market trends, market constraints and industry drivers.

This report includes detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global antirheumatics market namely: AbbVie Inc., Amgen Inc., Pfizer Inc., Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb, Merck & Co., Inc., UCB S.A. and Eli Lilly and Company

Scope of the Global Antirheumatics Pharmaceutical Market Forecast 2023 Report
This report provides detailed information about Global antirheumatics market including future market forecasts till 2023.
This report identifies the need for focusing on global antirheumatics market.
The report identifies the growth drivers and inhibitors for global antirheumatics market.
The report identifies various risks associated with global antirheumatics market.
This report has detailed profiles of 10 key players in Global antirheumatics market covering their business strategy, financial performance, future forecasts and SWOT analysis.
This report provides competitive landscape among top 10 key companies in Global antirheumatics market.
This report provides Porter’s Five Forces analysis for Global antirheumatics market.
This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Global antirheumatics market.
This report provides information about current and future trends for Global antirheumatics market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on